Shares of Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) have received an average rating of “Buy” from the six analysts that are covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $68.80.
Several research analysts have recently issued reports on QTTB shares. Wells Fargo & Company started coverage on shares of Q32 Bio in a research note on Wednesday, September 11th. They issued an “overweight” rating and a $95.00 target price on the stock. Guggenheim assumed coverage on shares of Q32 Bio in a report on Monday, June 17th. They set a “buy” rating and a $100.00 target price on the stock.
Institutional Trading of Q32 Bio
Q32 Bio Trading Up 3.2 %
NASDAQ QTTB opened at $44.79 on Friday. The company has a current ratio of 6.49, a quick ratio of 6.49 and a debt-to-equity ratio of 0.37. The business’s fifty day moving average price is $41.60. The company has a market cap of $534.88 million, a P/E ratio of -1.37 and a beta of -0.32. Q32 Bio has a 1 year low of $8.24 and a 1 year high of $53.79.
Q32 Bio (NASDAQ:QTTB – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.42). Equities research analysts forecast that Q32 Bio will post -11.76 EPS for the current fiscal year.
About Q32 Bio
Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.
Recommended Stories
- Five stocks we like better than Q32 Bio
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- 3 Tickers Leading a Meme Stock Revival
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- What Are the U.K. Market Holidays? How to Invest and Trade
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Q32 Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q32 Bio and related companies with MarketBeat.com's FREE daily email newsletter.